General Information of Drug (ID: DMO108N)

Drug Name
PMID29865878-Compound-58 Drug Info
Cross-matching ID
TTD Drug ID
DMO108N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M3258 DM6PI5B Multiple myeloma 2A83 Phase 1 [2]
Peptide analog 21 DMJDFS1 N. A. N. A. Patented [1]
Peptide analog 23 DMDU21R N. A. N. A. Patented [1]
Peptide analog 41 DM96KXE N. A. N. A. Patented [1]
PMID29865878-Compound-53 DM6JV1W N. A. N. A. Patented [1]
PMID29865878-Compound-55 DMY52ZB N. A. N. A. Patented [1]
PMID29865878-Compound-46 DMP3MXK N. A. N. A. Patented [1]
PMID29865878-Compound-48 DMVQTR2 N. A. N. A. Patented [1]
PMID29865878-Compound-51 DM0LXT2 N. A. N. A. Patented [1]
PMID29865878-Compound-49 DMK0GTV N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proteasome beta-8 (PS beta-8) TTEAD9J PSB8_HUMAN Inhibitor [1]

References

1 A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.
2 Clinical pipeline report, company report or official report of EMD Serono.